The FDA lifted a clinical hold on Intellia Therapeutics’ (NTLA.O) late-stage heart disease gene therapy trial Monday, sending shares up 7% in premarket trading.
The regulatory clearance removes a key overhang for the CRISPR gene-editing company and allows it to resume enrollment in its pivotal MAGNITUDE study testing nexiguran ziclumeran for transthyretin amyloidosis with cardiomyopathy.
Key Takeaways
- FDA removes clinical hold on MAGNITUDE Phase 3 trial
- Enhanced safety monitoring protocols now required for patients
- Both trials now cleared to complete enrollment goals
Market Reaction & Context
Intellia shares gained 7% to $14.12 in premarket trading following the announcement 1. The stock has climbed 20% over the past 12 months, outperforming the broader biotech sector which has struggled with regulatory setbacks and funding concerns.
Wall Street analysts maintain a moderate buy rating on the stock with an average price target of $19.73, suggesting further upside potential 2. HC Wainwright raised its target to $25 from $15, citing manageable clinical risk after the FDA’s decision.
Safety Measures and Trial Details
The FDA imposed the clinical hold in October 2025 after a patient in the MAGNITUDE trial experienced severe liver complications that later proved fatal 3. Intellia has now agreed to enhanced safety protocols including closer liver enzyme monitoring and exclusion of patients with certain liver abnormalities or heart ejection fractions below 25%.
The company will also provide guidance on short-term steroid treatments for patients who develop elevated liver enzymes during the initial dosing period. These measures apply to both the MAGNITUDE trial for heart disease and the previously cleared MAGNITUDE-2 study for nerve complications.
Management Commentary
“We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed to further enhance patient safety and allow us to continue to investigate nex-z in a broad ATTR-CM population,” said CEO John Leonard in a statement 4.
“With the resolution in January of the clinical hold on our MAGNITUDE-2 Phase 3 trial for patients with hereditary ATTR with polyneuropathy, our attention now turns to completing enrollment in both ongoing trials,” Leonard added.
Commercial Potential
The CRISPR-based therapy represents a potential one-time treatment for patients with transthyretin amyloidosis, a rare but serious condition affecting the heart and nervous system. If successful, nex-z could become the first approved gene-editing treatment for these conditions, addressing a significant unmet medical need.
Evercore ISI analysts called the safety adjustments “modest” and noted the hold was lifted relatively quickly with “minimal disruption to the clinical timeline” 3. However, they cautioned that the unknown cause of liver toxicity could create hesitancy among doctors and patients even after potential approval.
Outlook
Intellia now aims to complete enrollment of approximately 1,200 patients in MAGNITUDE and 60 patients in MAGNITUDE-2. The company maintains sufficient cash reserves of $605.1 million to fund operations through key milestones in the second half of 2027.
The regulatory clearance marks a significant step forward for Intellia’s partnership with Regeneron on developing CRISPR-based therapies, though liver safety will remain a key monitoring point throughout the trials.
Not investment advice. For informational purposes only.
References
1Darren Incorvaia (March 2, 2026). “FDA fully releases clinical hold on Intellia CRISPR gene therapy trials”. Fierce Biotech. Retrieved March 2, 2026.
2Emily J. Thompson (March 2, 2026). “Intellia Therapeutics Receives FDA Approval for Clinical Trial”. Intellectia.AI. Retrieved March 2, 2026.
3Darren Incorvaia (March 2, 2026). “FDA fully releases clinical hold on Intellia CRISPR gene therapy trials”. Fierce Biotech. Retrieved March 2, 2026.
4“Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM” (March 2, 2026). BioSpace. Retrieved March 2, 2026.